1. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Issue 1 (2nd January 2022) Authors: Pirosa, Maria C.; Zhang, Lu; Hitz, Felicitas; Novak, Urban; Hess, Dagmar; Terrot, Tatiana; Pascale, Mariarosa; Mazzucchelli, Luca; Bertoni, Francesco; Cavalli, Franco; Zucca, Emanuele; Stathis, Anastasios Journal: Leukemia & lymphoma Issue: Volume 63:Issue 1(2022) Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗